ChemoCentryx

Istotria

2022: Amgen bought ChemoCentryx for $3.7 billion

In early August 2022, Amgen and the biopharmaceutical ChemoCentryx, which specializes in the development of oral therapeutic drugs for autoimmune diseases, inflammatory disorders and cancer, entered into a final agreement under which Amgen will acquire ChemoCentryx for $52 per share. The transaction value is $3.7 billion.

The transaction is expected to be completed in Q4 2022. To do this, it will have to be approved by ChemoCentryx shareholders and regulators. PJT Partners acted as financial advisor to Amgen and Goldman Sachs for ChemoCentryx.

Amgen aims to unlock the potential of biology for patients suffering from serious diseases through the discovery, development, production and delivery of innovative therapeutic drugs for humans. This approach begins by using tools such as advanced human genetics to uncover complex aspects of the disease and understand the basics of human biology.

Amgen acquired a manufacturer of drugs for the treatment of rare blood vessel disease

Biopharmaceutical ChemoCentryx, is engaged in the commercialization and development of drugs for the treatment of inflammatory and autoimmune diseases and cancer. ChemoCentryx targets chemokine and chemoattractant systems for the discovery, development and commercialization of orally administered therapeutics.

In the US, ChemoCentryx markets Tavneos, the first approved oral inhibitor of complement receptor 5A as an adjunctive treatment for adult patients. It will be used in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. According to the executive director of ChemoCentryx Thomas Schall, the drug will be available in the next few weeks, the wholesale price for it will be $150-200 thousand for an annual course of treatment for one patient. An analyst at the American financial company Stifel Dae Ghosn Ha believes that by 2035 the drug will reach $1.3 billion in sales.^[1]

Notes